Oruka Therapeutics Inc (ORKA) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Public company logo of Oruka Corp (ORKA)

Oruka Therapeutics Inc (ORKA) develops long-acting antibodies for skin therapy amid a stable geopolitical backdrop. The GURU.Markets terminal displays the EV/EBITDA ratio for this industrial behemoth, which currently stands at approximately 0.00, serving as an indicator of market value. The company's financial model relies on attracting investment to develop biologics and conduct scientific research.

Oruka Corp - ORKA Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/17/2026)

ORKA (Oruka Therapeutics, Inc.): analytical breakdowns and indicator data

- market price and analyst price targets:
Summary company analysis:Oruka Pharma (ORKA)
Original product of Oruka Therapeutics

The EV/EBITDA ratio determines the total enterprise value, including debt, relative to operating profit, allowing investors to identify asset undervaluation through the Oruka Therapeutics Inc (ORKA) valuation trend. For the pre-revenue Oruka Therapeutics Inc (ORKA), this indicator becomes critical, as the absence of current revenue makes the market value dependent solely on the prospects of clinical trials for psoriasis drugs.